Telix and Kanazawa University Cleared to Commence Prostate Cancer Imaging Study in Japan
Telix Japan receives Clinical Trial Notification (CTN) clearance to commence a Phase I trial of its prostate cancer imaging product in Japan.
Telix FY2020 Results and Company Update Conference Call
Telix to present the Company’s FY2020 results together with an update on Telix’s operations.
Czech Republic Grants National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product
Telix announces the Ministry of Health of the Czech Republic is the first European health authority to grant a national authorization allowing the use of TLX591-CDx
Telix and Heidelberg University Hospital to Develop Next Generation Theranostics
Telix announces research cooperation agreement with Heidelberg University Hospital to develop next-generation theranostic radiopharmaceuticals for urologic oncology.
Industry Leaders’ Round-Table at SNMMI Mid-Winter Satellite Symposium
Telix CEO, Dr Christian Behrenbruch recently facilitated an international expert panel discussion at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mid-Winter Symposium entitled: “Ga-68 PSMA-11: Advances in Technology, Demand & Supply”.
Raphaël Ortiz Joins Telix as Chief Operating Officer, EMEA
Telix is pleased to announce that Raphaël Ortiz has joined the Company as Chief Operating Officer for Europe Middle East and Africa (EMEA).
First U.S. Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product
Telix Pharmaceuticals announces the first U.S. patients have been dosed in the Company’s Phase III ZIRCON trial.
Telix Pharmaceuticals Appoints Danielle Meyrick MD as CMO, Asia-Pacific
Telix is delighted to announce that Danielle Meyrick MD has joined its executive medical team in the role of Chief Medical Officer (CMO), Asia-Pacific.
ARTMS and Telix Pharmaceuticals Announce Successful Production of 68Ga PSMA-11 with Cyclotron Produced 68Ga from a Solid Target
ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer imaging product using multi-Curie quantities of cyclotron-produced Gallium-68 via ARTMS’ proprietary Quantum Irradiation System (QIS®) solid target system.
Telix Pharmaceuticals Files New Drug Submission with Health Canada for Prostate Cancer Imaging Product
Telix has filed a New Drug Submission (NDS) with Health Canada for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11).